Enanta Doses First Patient in Phase 1 Trial for Urticaria Drug EDP-978
Event summary
- Enanta Pharmaceuticals dosed the first participant in a Phase 1 trial for EDP-978, an oral KIT inhibitor targeting chronic urticaria.
- The trial will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults.
- Topline data from the Phase 1 study is expected in Q4 2026.
- EDP-978 is designed as a once-daily treatment for mast cell-driven diseases.
The big picture
Enanta's entry into Phase 1 trials for EDP-978 marks a strategic push into immunology, complementing its existing virology pipeline. The move underscores the company's shift toward developing treatments for inflammatory diseases, leveraging its chemistry-driven drug discovery capabilities. Success in this area could diversify Enanta's revenue streams beyond its existing HCV royalty agreements with AbbVie.
What we're watching
- Clinical Progress
- Whether EDP-978 demonstrates sufficient safety and efficacy in Phase 1 to advance to later-stage trials.
- Market Opportunity
- The potential of EDP-978 to address unmet needs in chronic urticaria, a condition with significant patient burden.
- Competitive Landscape
- How Enanta positions EDP-978 against existing and emerging therapies for mast cell-driven diseases.
Related topics